Polatuzumab vedotin is indicated for:
Population group: only adults (18 years old or older)
In combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) it is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
In combination with bendamustine and rituximab it is indicated for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Polatuzumab vedotin is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
